Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Kirk A Keegan"'
Autor:
F. Johannes P. van Valenberg, Antoine G. van der Heijden, Christopher J. Cutie, Sumeet Bhanvadia, Kirk A. Keegan, Shalaka Hampras, Hussein Sweiti, John C. Maffeo, Shu Jin, Albert Chau, Donald L. Reynolds, Crysti Iarossi, April Kelley, Xiang Li, Katharine A. Stromberg, J.P. Michiel Sedelaar, Jessica J.O. Steenbruggen, Diederik M. Somford, J. Alfred Witjes
Publikováno v:
European Urology Open Science, Vol 62, Iss , Pp 8-15 (2024)
Background and objective: Patients with intermediate-risk non–muscle-invasive bladder cancer (IR NMIBC) have a high risk of recurrence and need effective therapies to reduce the risk of disease recurrence or progression. This phase 1b study (NCT027
Externí odkaz:
https://doaj.org/article/d2cd291b695348ec8a7437420c222d46
Autor:
Mark D. Tyson, David Morris, Juan Palou, Oscar Rodriguez, Maria Carmen Mir, Rian J. Dickstein, Félix Guerrero-Ramos, Kristen R. Scarpato, Jason M. Hafron, Edward M. Messing, Christopher J. Cutie, John C. Maffeo, Bradley Raybold, Albert Chau, Katharine A. Stromberg, Kirk A. Keegan
Publikováno v:
Journal of Urology. 209:890-900
Autor:
Mark D. Tyson, David Morris, Juan Palou, Oscar Rodriguez, Maria Carmen Mir, Rian J. Dickstein, Félix Guerrero-Ramos, Kristen R. Scarpato, Jason M. Hafron, Edward M. Messing, Christopher J. Cutie, John C. Maffeo, Bradley Raybold, Albert Chau, Katharine A. Stromberg, Kirk A. Keegan
Publikováno v:
Journal of Urology. 209:900-900
Autor:
Alan Boyd, Tracy M. Downs, Brian R. Lane, Michael Woods, Brant A. Inman, Joseph Mashni, Gary D. Steinberg, Kirk A. Keegan, Alexander Sankin, Joseph E. Busby, Stephen A. Boorjian, Robert S. Svatek, Richard Philipson, Paul L. Crispen, Michael A. O’Donnell, Seth P. Lerner, Daniel J. Canter, Colin P.N. Dinney, Vikram M. Narayan, Yair Lotan, Tracey L. Krupski, Michael S. Cookson, Leonard G. Gomella, Ashish M. Kamat, David Sawutz, Lawrence Karsh, Michael B. Williams, F. Peter Treasure, Ruth Coll, Gennady Bratslavsky, Thomas J. Guzzo, Adam Luchey, Mehrdad Alemozaffar, Trinity J. Bivalacqua, Michael A. Poch, Jeffrey S. Montgomery, Badrinath R. Konety, Nigel Parker, Anne Schuckman, Seppo Ylä-Herttuala, Neal D. Shore, Gordon D. Brown, Gerald L. Andriole
Publikováno v:
The Lancet Oncology. 22:107-117
Summary Background BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDN
Publikováno v:
Urology Practice. 8:65-70
Introduction:To assess and improve quality of care, the Commission on Cancer developed 3 evidence-based quality measures for the treatment of muscle invasive bladder cancer. We sought to as...
Autor:
Amy N. Luckenbaugh, Mary E. Hall, Christopher J.D. Wallis, Kelvin A. Moses, Aaron A. Laviana, Zachary Klaassen, Kirk A. Keegan, Heather L. Huelster
Publikováno v:
OncoTargets and Therapy. 13:3571-3581
Introduction The treatment landscape for patients with metastatic hormone-sensitive prostate cancer (mHSPC) has changed dramatically in the past five years, despite little change in the preceding 20 years. Such rapid change can make it difficult for
Autor:
F. Johannes P. van Valenberg, Toine van der Heijden, Christopher Cutie, Sumeet Kaur Bhanvadia, Kirk A. Keegan, Shalaka Hampras, Hussein Sweiti, John Maffeo, Shu Jin, Albert Chau, Don Reynolds, Crysti Iarossi, April Kelley, Xiang Li, Katherine Stromberg, Michiel Sedelaar, Jessica Steenbruggen, Diederik Meindert Somford, Alfred Alfred Witjes
Publikováno v:
Journal of Clinical Oncology. 41:505-505
505 Background: TAR-200 is a novel intravesical drug delivery system designed to provide a continuous, slow release of gemcitabine within the bladder. Prolonged gemcitabine exposure over days, instead of hours, such as with current standard intravesi
Autor:
Anirban P. Mitra, Vikram M. Narayan, Sharada Mokkapati, Tanner Miest, Stephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety, Neal D. Shore, Leonard G. Gomella, Ashish M. Kamat, Trinity J. Bivalacqua, Jeffrey S. Montgomery, Seth P. Lerner, J. Erik Busby, Michael Poch, Paul L. Crispen, Gary D. Steinberg, Anne K. Schuckman, Tracy M. Downs, Robert S. Svatek, Joseph Mashni, Brian R. Lane, Thomas J. Guzzo, Gennady Bratslavsky, Lawrence I. Karsh, Michael E. Woods, Gordon A. Brown, Daniel Canter, Adam Luchey, Yair Lotan, Tracey Krupski, Brant A. Inman, Michael B. Williams, Michael S. Cookson, Kirk A. Keegan, Gerald L. Andriole, Alexander I. Sankin, Alan Boyd, Michael A. O'Donnell, Richard Philipson, Seppo Ylä-Herttuala, David Sawutz, Nigel R. Parker, David J. McConkey, Colin P.N. Dinney
Publikováno v:
Eur Urol
A recent phase 3 trial of intravesical nadofaragene firadenovec reported a promising complete response rate for patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer. This study examined the ability of antiadenovirus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9deece93273da2ab7b3a339994b2f19
https://europepmc.org/articles/PMC8891058/
https://europepmc.org/articles/PMC8891058/
Autor:
X. Li, Stephen B. Williams, Kirk A. Keegan, Wei Zhu, Lang A O'Dondi, Daniel E. Spratt, N. Beeharry, Christopher Cutie, Milin Acharya, Rachel Stewart, Bradley Raybold
Publikováno v:
Journal of Urology. 206
INTRODUCTION AND OBJECTIVE:The standard of care for patients with muscle-invasive bladder cancer (MIBC) consists of neoadjuvant chemotherapy and radical cystectomy (RC) or chemoradiotherapy (CRT). ...
Autor:
Gary D. Steinberg, Anne Schuckman, Yair Lotan, Paul L. Crispen, Michael B. Williams, Seppo Ylä-Herttuala, Richard Philipson, Daniel Canter, Michael A. O’Donnell, Lawrence Karsh, Alan Boyd, Vikram M. Narayan, Kirk A. Keegan, Gordon D. Brown, Nigel Parker, Jeffrey S. Montgomery, Michael S. Cookson, David Sawutz, Michael Woods, Joseph E. Busby, Stephen A. Boorjian, Tracy M. Downs, Colin P.N. Dinney, Neal D. Shore, Leonard G. Gomella, Joseph Mashni, Gennady Bratslavsky, Gerald L. Andriole, Brant A. Inman, Alexander Sankin, Tracey L. Krupski, Ashish M. Kamat, Badrinath R. Konety, Seth P. Lerner, Robert S. Svatek, Brian R. Lane, Anirban P. Mitra, Michael A. Poch, Mehrdad Alemozaffar, Mindy Yang, Trinity J. Bivalacqua, Thomas J. Guzzo, Adam Luchey
Publikováno v:
Journal of Urology. 206
INTRODUCTION AND OBJECTIVE:Nadofaragene firadenovec is a recombinant adenoviral vector-based intravesical therapeutic that delivers a copy of human IFNα2b gene to urothelial cells. A recent phase 3...